Evidence map›Paper›PMID 39319218›Full record

ArticleOncoTargets and therapy2024

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from

Nadiya Nurul Afifah, Lanny Indah Permatasari, Ajeng Diantini, Ruri Intania, Indra Wijaya, Hideru Obinata, Melisa Intan Barliana

Abstract read
In one paragraph

Article in OncoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nadiya Nurul AfifahDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.ORCID 0000-0003-1817-436X
Lanny Indah PermatasariDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.ORCID 0009-0003-1547-5922
Ajeng DiantiniDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.
Ruri IntaniaDivision of Pulmonology and Respiratory, Dr.H.A Rotinsulu, Lung Hospital, Bandung, Indonesia.
Indra WijayaDivision of Hematology and Medical Oncology, Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.ORCID 0000-0002-9446-2307
Hideru ObinataEducation and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Melisa Intan BarlianaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.ORCID 0000-0003-0015-9604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Individual responses to platinum-based treatment for Non-Small Cell Lung Cancer (NSCLC) are influenced by genetic polymorphisms, including Single Nucleotide Polymorphisms (SNPs). This study aimed to explore the role of ERCC2 in the Nucleotide Excision Repair (NER) pathway for platinum-based chemotherapy in NSCLC. While Patients and Methods: This study recruited 82 NSCLC patients with wildtype mutations of Results: The results of this study showed the presence of genotype variation among the subjects, with frequency distribution as follows: AA genotype (82.9%), AC genotype (15.9%), and CC genotype (1.2%). The analysis of the association between Conclusion: This study did not find statistically significant associations between

Indexed as

ERCC2genetic polymorphismIndonesiaplatinum-basedRECIST 1.1

Identifiers

PMID39319218
PMCPMC11421434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.